RU2015151135A - Инъекционные гелевые нанокаркасы для лечения диабета - Google Patents
Инъекционные гелевые нанокаркасы для лечения диабета Download PDFInfo
- Publication number
- RU2015151135A RU2015151135A RU2015151135A RU2015151135A RU2015151135A RU 2015151135 A RU2015151135 A RU 2015151135A RU 2015151135 A RU2015151135 A RU 2015151135A RU 2015151135 A RU2015151135 A RU 2015151135A RU 2015151135 A RU2015151135 A RU 2015151135A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- particles
- insulin
- composition according
- acid
- Prior art date
Links
- 238000002347 injection Methods 0.000 title claims 3
- 239000007924 injection Substances 0.000 title claims 3
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 15
- 239000002245 particle Substances 0.000 claims 12
- 102000004877 Insulin Human genes 0.000 claims 6
- 108090001061 Insulin Proteins 0.000 claims 6
- 229940125396 insulin Drugs 0.000 claims 6
- 229920000642 polymer Polymers 0.000 claims 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000008103 glucose Substances 0.000 claims 5
- 239000011159 matrix material Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 102000016938 Catalase Human genes 0.000 claims 3
- 108010053835 Catalase Proteins 0.000 claims 3
- 108010015776 Glucose oxidase Proteins 0.000 claims 3
- 239000004366 Glucose oxidase Substances 0.000 claims 3
- 229940039227 diagnostic agent Drugs 0.000 claims 3
- 239000000032 diagnostic agent Substances 0.000 claims 3
- 229940116332 glucose oxidase Drugs 0.000 claims 3
- 235000019420 glucose oxidase Nutrition 0.000 claims 3
- 239000004026 insulin derivative Substances 0.000 claims 3
- 230000000069 prophylactic effect Effects 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 229920006237 degradable polymer Polymers 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 239000004971 Cross linker Substances 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 108010004903 glycosylated serum albumin Proteins 0.000 claims 1
- 238000012667 polymer degradation Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361817752P | 2013-04-30 | 2013-04-30 | |
| US61/817,752 | 2013-04-30 | ||
| US201361864069P | 2013-08-09 | 2013-08-09 | |
| US61/864,069 | 2013-08-09 | ||
| PCT/US2014/035927 WO2014179344A1 (en) | 2013-04-30 | 2014-04-29 | Injectable nano-network gels for diabetes treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015151135A true RU2015151135A (ru) | 2017-06-02 |
Family
ID=51843897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015151135A RU2015151135A (ru) | 2013-04-30 | 2014-04-29 | Инъекционные гелевые нанокаркасы для лечения диабета |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160067190A1 (https=) |
| EP (1) | EP2991673A4 (https=) |
| JP (1) | JP2016517885A (https=) |
| KR (1) | KR20160024853A (https=) |
| CN (1) | CN105813652A (https=) |
| AU (1) | AU2014260024B2 (https=) |
| BR (1) | BR112015027561A8 (https=) |
| HK (2) | HK1221415A1 (https=) |
| MX (1) | MX2015015079A (https=) |
| RU (1) | RU2015151135A (https=) |
| WO (1) | WO2014179344A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014153114A1 (en) * | 2013-03-14 | 2014-09-25 | Fred Hutchinson Cancer Research Center | Compositions and methods to modify cells for therapeutic objectives |
| JP2017538728A (ja) * | 2014-12-19 | 2017-12-28 | ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎ Ｉｎｄｕｓｔｒｉｅｓ， Ｉｎｃ． | イオントフォレシスを用いた生物活性分子の眼内送達 |
| CN104740641B (zh) * | 2015-04-08 | 2019-02-01 | 烟台大学 | 一种糖敏感的缓控释微球组合物及其制备方法 |
| RU2719584C2 (ru) * | 2015-04-21 | 2020-04-21 | Норт Каролина Стейт Юниверсити | Глюкозочувствительная система доставки инсулина с использованием чувствительных к гипоксии нанокомпозитов |
| JP6757464B2 (ja) * | 2016-07-21 | 2020-09-16 | ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． | 注射用組成物 |
| WO2018085809A1 (en) | 2016-11-07 | 2018-05-11 | North Carolina State University | Patch loaded with dual-sensitive vesicles for enhanced glucose-responsive insulin delivery |
| EP3799865B1 (en) * | 2016-12-05 | 2022-06-15 | North Carolina State University | Core-shell microneedle devices and uses thereof |
| CN106668840B (zh) * | 2017-02-10 | 2020-02-14 | 南通大学 | 一种胰岛素控释药物及其制备方法与应用 |
| WO2019055594A1 (en) * | 2017-09-13 | 2019-03-21 | North Carolina State University | BRUSHING ADIPOSE TISSUE INDUCED LOCALLY BY MICRO-NEEDLE STAMPS FOR THE TREATMENT OF OBESITY |
| CN111629746B (zh) * | 2017-11-21 | 2024-04-16 | 北卡罗来纳州立大学 | 具有超快响应的用于葡萄糖触发胰岛素递送的电荷可切换聚合物储库 |
| EP3735262A4 (en) * | 2018-01-03 | 2021-09-29 | Penn State Research Foundation | GLUCOSE OXIDASE COMPOSITIONS AS ANTICONVULSIVE FOR NEWBORN |
| CN111629715A (zh) | 2018-01-18 | 2020-09-04 | 弗莱德哈钦森癌症研究中心 | 通过调节细胞活化状态改变体内免疫细胞的炎症状态 |
| CN111195238A (zh) * | 2018-10-31 | 2020-05-26 | 南方医科大学 | 一种用于胰岛素口服递送的聚电解质复合物 |
| US20220204654A1 (en) * | 2019-04-25 | 2022-06-30 | Massachusetts Institute Of Technology | Cyclodextrin supramolecular scaffolds and uses thereof |
| CN115350267B (zh) * | 2022-07-19 | 2025-01-14 | 深圳大学 | 一种级联催化型纳米治疗剂及其制备方法和应用 |
| CN115252537B (zh) * | 2022-09-01 | 2026-02-06 | 西北大学 | 用于糖尿病伤口的双层微针贴片及其制备方法 |
| CN116474162B (zh) * | 2023-04-28 | 2024-08-16 | 吉林大学 | 一种用于糖尿病慢性创伤修复的自修复水凝胶的制备方法 |
| US20250025411A1 (en) * | 2023-07-21 | 2025-01-23 | Massachusetts Institute Of Technology | Readily soluble and thermostable glucagon formulations and delivery for mini-dosing and closed -loop prophylactic treatment of hypoglycemia |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US6497903B1 (en) * | 1996-07-01 | 2002-12-24 | Wilhelmus Everhardus Hennink | Hydrolysable hydrogels for controlled release |
| AU2003301064A1 (en) * | 2002-12-17 | 2004-07-14 | Massachusetts Institute Of Technology | Stimuli-responsive systems for controlled drug delivery |
| WO2006088473A2 (en) * | 2004-04-23 | 2006-08-24 | Panduranga Rao Koritala | Microcapsules and nanocapsules for the transmucosal delivery of therapeutic and diagnostic agents |
| EP1595534A1 (en) * | 2004-05-13 | 2005-11-16 | Universiteit Utrecht Holding B.V. | Gel composition comprising charged polymers |
| TWI394580B (zh) * | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| JP5841708B2 (ja) * | 2008-07-01 | 2016-01-13 | 日東電工株式会社 | 表面被覆微粒子の医薬組成物 |
-
2014
- 2014-04-29 US US14/787,652 patent/US20160067190A1/en not_active Abandoned
- 2014-04-29 MX MX2015015079A patent/MX2015015079A/es unknown
- 2014-04-29 WO PCT/US2014/035927 patent/WO2014179344A1/en not_active Ceased
- 2014-04-29 EP EP14792285.0A patent/EP2991673A4/en not_active Withdrawn
- 2014-04-29 RU RU2015151135A patent/RU2015151135A/ru not_active Application Discontinuation
- 2014-04-29 KR KR1020157034126A patent/KR20160024853A/ko not_active Withdrawn
- 2014-04-29 HK HK16109650.4A patent/HK1221415A1/zh unknown
- 2014-04-29 AU AU2014260024A patent/AU2014260024B2/en not_active Ceased
- 2014-04-29 HK HK16110684.2A patent/HK1222546A1/zh unknown
- 2014-04-29 BR BR112015027561A patent/BR112015027561A8/pt not_active Application Discontinuation
- 2014-04-29 JP JP2016511809A patent/JP2016517885A/ja active Pending
- 2014-04-29 CN CN201480037463.3A patent/CN105813652A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN105813652A (zh) | 2016-07-27 |
| JP2016517885A (ja) | 2016-06-20 |
| BR112015027561A8 (pt) | 2019-12-24 |
| MX2015015079A (es) | 2016-07-05 |
| EP2991673A1 (en) | 2016-03-09 |
| HK1222546A1 (zh) | 2017-07-07 |
| US20160067190A1 (en) | 2016-03-10 |
| EP2991673A4 (en) | 2016-12-21 |
| WO2014179344A1 (en) | 2014-11-06 |
| AU2014260024B2 (en) | 2016-09-15 |
| BR112015027561A2 (pt) | 2017-07-25 |
| KR20160024853A (ko) | 2016-03-07 |
| AU2014260024A1 (en) | 2015-11-19 |
| HK1221415A1 (zh) | 2017-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015151135A (ru) | Инъекционные гелевые нанокаркасы для лечения диабета | |
| JP2016517885A5 (https=) | ||
| Fernández-Serra et al. | Hydrogels for neuroprotection and functional rewiring: a new era for brain engineering | |
| WO2016172320A8 (en) | Glucose-responsive insulin delivery system using hyoxia-sensitive nanocomposites | |
| RU2008131300A (ru) | Длительное высвобождение нейрегулина для улучшения сердечной функции | |
| BRPI0513243A (pt) | composições oftálmicas e métodos para tratar condições oftálmicas | |
| WO2025112235A1 (zh) | 一种包裹性透明质酸凝胶组合物及其制备方法与应用 | |
| CN103881026B (zh) | 一种聚n-乙烯基吡咯烷酮微凝胶及其制备方法和用途 | |
| WO2023129738A3 (en) | Modified polysaccharide polymers and related compositions and methods thereof | |
| Heyns et al. | Glucose-responsive microgel comprising conventional insulin and curcumin-laden nanoparticles: A potential combination for diabetes management | |
| EP2067484A2 (de) | Verfahren zur herstellung von insulin in form einer oralen zubereitung | |
| CN102824305A (zh) | 阿奇霉素滴眼液及其制备方法 | |
| CN121152643A (zh) | 用于组织修复的组合物 | |
| CN106138011A (zh) | 碳酸钙/透明质酸复合药物载体及其制备方法 | |
| CN105726471A (zh) | 一种含维生素c药物组合物及其制备方法 | |
| CN108778258B (zh) | 用于提供靶向结肠的口服胰岛素的被微生物群激活的生物可降解共价基质和获得这些基质的方法 | |
| CN103720714B (zh) | 一种制作灵长类动物视网膜色素变性疾病模型的方法 | |
| CN1843503A (zh) | 一种滴眼剂 | |
| Friedmann | Calcium hydroxylapatite (Radiesse®) | |
| CN1616074A (zh) | 灵芝孢子油脂肪乳剂 | |
| Klos et al. | Cutaneous adverse drug reaction to heparins with hypereosinophilia and high IgE level | |
| CN1579417A (zh) | 一种复方脱水利尿药物组合物及其制备方法 | |
| The et al. | Adherence of patients to antihypertensive therapy with combination of perindopril and indapamide according to data of the FORSAGE Program | |
| RU2275917C1 (ru) | Способ профилактики прогрессирования близорукости | |
| Kossovsky | Can the silicone controversy be resolved with rational certainty? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20191015 |